These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 16476953)

  • 21. Analysis of neutralizing antibodies to therapeutic interferon-beta in multiple sclerosis patients: a comparison of three methods in a large Australasian cohort.
    McKay F; Schibeci S; Heard R; Stewart G; Booth D
    J Immunol Methods; 2006 Mar; 310(1-2):20-9. PubMed ID: 16448664
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Neutralizing antibodies in patients with multiple sclerosis treated with interferon beta-1b].
    Río J; Barberà N; Tintoré M; Brieva L; Montalbán X
    Med Clin (Barc); 2000 Feb; 114(5):169-70. PubMed ID: 10738721
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Persistence of neutralizing antibodies after discontinuation of IFNbeta therapy in patients with relapsing-remitting multiple sclerosis.
    Petersen B; Bendtzen K; Koch-Henriksen N; Ravnborg M; Ross C; Sorensen PS;
    Mult Scler; 2006 Jun; 12(3):247-52. PubMed ID: 16764336
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent.
    Sominanda A; Hillert J; Fogdell-Hahn A
    J Neurol Neurosurg Psychiatry; 2008 Jan; 79(1):57-62. PubMed ID: 17911184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-interferon-beta neutralising activity is not entirely mediated by antibodies.
    Gilli F; Marnetto F; Caldano M; Valentino P; Granieri L; Di Sapio A; Capobianco M; Sala A; Malucchi S; Kappos L; Lindberg RL; Bertolotto A
    J Neuroimmunol; 2007 Dec; 192(1-2):198-205. PubMed ID: 17950468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.
    Grossberg SE; Oger J; Grossberg LD; Gehchan A; Klein JP
    J Interferon Cytokine Res; 2011 Mar; 31(3):337-44. PubMed ID: 21226608
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation.
    Sellebjerg F; Krakauer M; Hesse D; Ryder LP; Alsing I; Jensen PE; Koch-Henriksen N; Svejgaard A; Soelberg Sørensen P
    Eur J Neurol; 2009 Dec; 16(12):1291-8. PubMed ID: 19558503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot study.
    Millonig A; Rudzki D; Hölzl M; Ehling R; Gneiss C; Künz B; Berger T; Reindl M; Deisenhammer F
    Mult Scler; 2009 Aug; 15(8):977-83. PubMed ID: 19465447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neutralizing antibodies explain the poor clinical response to interferon beta in a small proportion of patients with multiple sclerosis: a retrospective study.
    Sbardella E; Tomassini V; Gasperini C; Bellomi F; Cefaro LA; Morra VB; Antonelli G; Pozzilli C
    BMC Neurol; 2009 Oct; 9():54. PubMed ID: 19825153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determination of interferon beta neutralizing antibodies in multiple sclerosis: improvement of clinical sensitivity of a cytopathic effect assay.
    Massart C; Gibassier J; de Seze J; Debouverie M; Moreau T; Pelletier J; Vermersch P; Edan G
    Clin Chim Acta; 2008 May; 391(1-2):98-101. PubMed ID: 18249193
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incorporation of an interferon-β neutralizing antibody assay into routine clinical practice.
    Farrell RA; Espasandin M; Lakdawala N; Creeke PI; Worthington V; Giovannoni G
    Mult Scler; 2011 Nov; 17(11):1333-40. PubMed ID: 21685230
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neutralizing antibodies to multiple sclerosis treatments.
    Rossman HS
    J Manag Care Pharm; 2004 Jun; 10(3 Suppl B):S12-9. PubMed ID: 15253685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis.
    Croze E; Yamaguchi KD; Knappertz V; Reder AT; Salamon H
    Pharmacogenomics J; 2013 Oct; 13(5):443-51. PubMed ID: 22711062
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lack of interferon-beta bioactivity is associated with the occurrence of relapses in multiple sclerosis.
    van der Voort LF; Visser A; Knol DL; Oudejans CB; Polman CH; Killestein J
    Eur J Neurol; 2009 Sep; 16(9):1049-52. PubMed ID: 19486142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.
    Bertolotto A; Malucchi S; Sala A; Orefice G; Carrieri PB; Capobianco M; Milano E; Melis F; Giordana MT
    J Neurol Neurosurg Psychiatry; 2002 Aug; 73(2):148-53. PubMed ID: 12122172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MxA mRNA quantification and disability progression in interferon beta-treated multiple sclerosis patients.
    Serana F; Imberti L; Amato MP; Comi G; Gasperini C; Ghezzi A; Martinelli V; Provinciali L; Rottoli MR; Sotgiu S; Stecchi S; Vecchio M; Zaffaroni M; Cordioli C; Capra R
    PLoS One; 2014; 9(4):e94794. PubMed ID: 24733382
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Persistency of neutralizing antibodies depends on titer and interferon-beta preparation.
    Hegen H; Schleiser M; Gneiss C; Di Pauli F; Ehling R; Kuenz B; Lutterotti A; Berger T; Deisenhammer F
    Mult Scler; 2012 May; 18(5):610-5. PubMed ID: 22013146
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation between anti-interferon-β binding and neutralizing antibodies in interferon-β-treated multiple sclerosis patients.
    Jensen PE; Sellebjerg F; Søndergaard HB; Sørensen PS
    Eur J Neurol; 2012 Oct; 19(10):1311-7. PubMed ID: 22564111
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity of interferon beta: differences among products.
    Bertolotto A; Deisenhammer F; Gallo P; Sölberg Sørensen P
    J Neurol; 2004 Jun; 251 Suppl 2():II15-II24. PubMed ID: 15264108
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparative study of the relative bioavailability of different interferon beta preparations.
    Deisenhammer F; Mayringer I; Harvey J; Dilitz E; Gasse T; Stadlbauer D; Reindl M; Berger T
    Neurology; 2000 Jun; 54(11):2055-60. PubMed ID: 10851362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.